key: cord-0961598-om6ipwlv
authors: Chen, Jungang; Dai, Lu; Kendrick, Samantha; Post, Steven R.; Qin, Zhiqiang
title: The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
date: 2022-03-15
journal: Antimicrob Agents Chemother
DOI: 10.1128/aac.02395-21
sha: f577136c2b54267f1423e75dfc0f30ee04fc3e5f
doc_id: 961598
cord_uid: om6ipwlv

Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways.

The effects of remdesivir and molnupiravir on KSHV lytic reactivation. (A-B) The cytotoxicity of remdesivir and molnupiravir on BCBL-1 and BCP-1 cells was examined at 72 h posttreatment using the WST-1 cell proliferation assays (Roche). (C-E) Cells were treated with a dose range of remdesivir or molnupiravir (20 mM), respectively, for 72 h, then the transcripts of representative lytic genes were quantified by using qRT-PCR. Protein expression was measured by using Western blot. (F) The supernatants from cells treated with remdesivir at CC 50 concentration were collected to infect naive HEK293T (Continued on next page) and lytic replication phases, both of which are essential for tumorigenesis (11) . Compared with latency when only a limited number of viral genes are expressed, lytic reactivation permits the expression of the majority of viral genes, in a sequential fashion of immediate early, early, and late genes (12, 13) . Increasing data report that lytic reactivation requires the involvement of several cellular signaling pathways, such as AMPK and STAT3. A previous study showed AMPK suppressed KSHV infection and replication, which was further supported by the observation that an AMPK inhibitor, compound C, augmented viral lytic gene expression and subsequent virion production (14) . In contrast, knockdown or chemical inhibition of STAT3 resulted in KSHV lytic activation via suppression of KAP1 (15) . Similarly, STAT3 inhibition was previously shown to induce EBV lytic activation in B lymphocytes (16) .

In this study, we sought to determine whether remdesivir and molnupiravir treatment affects lytic reactivation of KSHV and EBV. Initially, the cytotoxicity of remdesivir and molnupiravir against two KSHV-infected primary effusion lymphoma (PEL) cell lines, BCBL-1 and BCP-1, were evaluated at 72 h posttreatment by the WST-1 assay as described previously (17) . The data indicated cytotoxic concentrations (CC 50 ) of remdesivir for BCBL-1 and BCP-1 of 1.2 mM and 2.6 mM (Fig. 1A) , respectively. In contrast, the CC 50 of molnupiravir for these cells was around 20 mM (Fig. 1B) . Next, qRT-PCR analysis showed remdesivir treatment significantly induced the expression of viral lytic genes, including RTA (immediate early gene), PF (early gene), and ORF26 (late gene), in a dose-dependent manner in both PEL cell lines (Fig. 1C ). In contrast, molnupiravir treatment showed little change of viral lytic gene expression even at the dose of CC 50 (Fig. 1D ). We then confirmed remdesivir treatment increased the expression of ORF45 (immediate early gene) and ORF26 (late gene) at the protein level using the Western blot (WB) assay in both PEL cell lines (Fig. 1E) . To measure the production of infectious virion, qPCR assay was used to test viral DNA levels extracted from HEK293 cells, which were infected by the supernatants from BCBL-1 and BCP-1 cells following incubation with each of the compounds. Our findings demonstrate remdesivir treatment effectively increased virion production to a similar level of sodium butyrate (NaB), a classical chemical inducer for KSHV reactivation (Fig. 1F) .

To investigate the underlying mechanisms, we examined the activities of several key intracellular signaling pathways associated with KSHV lytic replication in remdesivir-treated PEL cells by using the WB assay. Our results indicated that remdesivir treatment mainly increased AMPK phosphorylation while decreasing STAT3 phosphorylation in a dose-dependent fashion in BCBL-1 cells (Fig. 1G) . Moreover, the addition of dorsomorphin (an AMPK inhibitor) or colivelin TFA (a STAT3 inducer) blocked remdesivir-induced expression of viral lytic proteins ORF45 and ORF26 (Fig. 1H) , confirming the involvement of AMPK and STAT3 signaling in remdesivirinduced KSHV lytic reactivation. The impact of dorsomorphin and colivelin TFA on AMPK and STAT3 signaling activities, respectively, were validated by WB assay (Fig. 1I ).

In addition, we examined the effects of remdesivir on EBV lytic reactivation in EBV1 lymphoma cells. Three different types of EBV1 lymphoma cell lines, RPMI 6666 (Hodgkin's lymphoma), Akata (Burkitt's lymphoma), and VAL (diffuse large B-cell lymphoma) were used as our model. We found that the CC 50 of remdesivir for these EBV1 lymphoma cell lines was around 10 mM ( Fig. 2A) . Remdesivir treatment increased the expression of viral lytic genes, such as BZLF1 (immediate early gene) and BHFR1 (early gene), in all of three EBV1 lymphoma cell lines as quantified by qRT-PCR (Fig. 2B) . The WB results indicated that remdesivir treatment mainly reduced STAT3 but increased p38 MAPK phosphorylation from EBV1 lymphoma cells (Fig. 2C) , two signaling pathways that are associated with EBV reactivation (16, 18) . These data indicate that remdesivir may also induce EBV lytic reactivation from latently infected cells. In contrast, molnupiravir treatment had limited cytotoxicity on EBV1 lymphoma cell lines (CC 50 20 mM, Fig. 2D ). Interestingly, molnupiravir treatment FIG 1 Legend (Continued) cells, then viral genome levels were quantified by using qPCR with LANA specific primers. The sodium butyrate (NaB, 0.3 mM) was used as a positive control. The CC 50 for each compound was calculated using GraphPad Prism 5.0. (G) BCBL-1 cells were exposed to a dose range of remdesivir for 72 h, then protein expression was measured by using Western blot. (H) Cells were treated with remdesivir (3 mM) in combination with dorsomorphin (an AMPK inhibitor) or colivelin TFA (a STAT3 activator), respectively, for 48 h, then protein expression was measured by using Western blot. (I) Cells were treated with dorsomorphin or colivelin TFA, respectively, for 48 h, then protein expression was measured by using Western blot. Error bars represent the SD for 3 independent experiments. *, P , 0.05; **, P , 0.01 (two-tailed Student's t test). significantly reduced EBV lytic gene expression from these lymphoma cells (Fig. 2E) , although the mechanisms remain unknown.

In summary, we evaluated the effects of two recently FDA-approved anti-COVID-19 drugs, remdesivir and molnupiravir, on lytic reactivation of human oncogenic herpesviruses. Although both drugs target SARS-CoV-2 RNA polymerase and interfere with viral replication, only remdesivir strongly induces KSHV and EBV lytic reactivation. These data suggest a potential risk of treating COVID-19 patients with preexisting oncogenic herpesvirus infection with remdesivir. Reactivation of these preexisting infections may increase viral pathogenesis and tumorigenesis, especially for immunocompromised or immunosuppressed patients that are already at an elevated risk of KSHV/EBV-associated malignancies. Therefore, continuous monitoring of viral loads and assessing risk of developing virus-associated malignancies are necessary for these patients with remdesivir treatment, even after they have fully recovered from COVID-19.

Supplemental material is available online only. SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

This work was supported by NIH/NCI R01CA228166, the Arkansas Bioscience Institute, the major research component of the Arkansas Tobacco Settlement Proceeds Act of 2000. Funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We declare that we have no conflicts of interest.

Clinical features and outcomes of adults with coronavirus disease 2019: a systematic review and pooled analysis of the literature

High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19

Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients

Acute retinal necrosis from reactivation of varicella zoster virus following BNT162b2 mRNA COVID-19 vaccination

A case of acute retinal necrosis associated with reactivation of varicella zoster virus after COVID-19 vaccination

Reactivation of herpes zoster after vaccination with an inactivated vaccine: a case report from Nepal

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited

Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19

WHO International Agency for Research on Cancer Monograph Working Group

The role of gammaherpesviruses in cancer pathogenesis

Regulation of the latent-lytic switch in Epstein-Barr virus

Regulation of KSHV latency and lytic reactivation

Suppression of Kaposi's sarcomaassociated herpesvirus infection and replication by 5 '-AMP-activated protein kinase

STAT3 regulates lytic activation of Kaposi's sarcoma-associated herpesvirus

Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes

Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression

PKC theta and p38 MAPK activate the EBV lytic cycle through autophagy induction